98%
921
2 minutes
20
Objective: We explored the prevalence and determinants of hypoglycemia in patients with gestational diabetes mellitus (GDM), and we developed and validated a nomogram prediction model.
Methods: We extracted data from the clinical records of 475 patients with GDM attending the tertiary class A specialized hospital in Zhuhai City between December 2021 and June 2023 for a modeling group, and we used data of another cohort of 204 GDM cases for a validation group. We conducted a logistic regression analysis to identify factors associated with hypoglycemia in patients with GDM and generated a risk prediction model presented as a nomogram. The model was validated using data from the patients in the validation group.
Results: The prevalence of hypoglycemia in the study population was 25.5%. Our risk prediction model incorporated four predictors, including a fasting oral glucose tolerance test (OGTT) value, the number of fetuses, the presence or absence of intrahepatic cholestasis of pregnancy (ICP), and the blood glucose level self-monitoring frequency. The area under the receiver operating characteristic (ROC) curve was 0.786 for the modeling set and 0.742 for the validation set. The Brier score was 0.155, and the calibration slope was 0.750, demonstrating satisfactory clinical usefulness of the model. Moreover, a decision curve analysis further supported our model's clinical relevance.
Conclusion: The prevalence of hypoglycemia in patients with GDM is considerable. Our nomogram prediction model demonstrated good performance for identifying high-risk individuals. The model could serve as a valuable tool for screening and managing hypoglycemia among patients with GDM.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105396 | PMC |
http://dx.doi.org/10.1186/s12884-025-07740-8 | DOI Listing |
Minerva Cardiol Angiol
September 2025
Department of Pharmacology, MGM Medical College and Hospital, MGM Institute of Health Sciences, Nerul, Navi Mumbai, India.
Liraglutide is a key therapeutic agent in managing type 2 diabetes mellitus (T2DM), with benefits extending beyond glycemic control to address cardiovascular and renal comorbidities. As T2DM prevalence rises globally, the need for medications that provide comprehensive health benefits becomes increasingly important. Liraglutide, a GLP-1 receptor agonist, has demonstrated effectiveness in reducing cardiovascular events, especially among patients with high cardiovascular risk, such as those with a prior history of myocardial infarction or stroke.
View Article and Find Full Text PDFG Ital Nefrol
August 2025
Infermiere Professionale SSD Nefrologia e Dialisi P.O. Soverato, ASP CZ.
Management of diabetes mellitus in hemodialysis is highly complex due to increased glycemic variability and hypoglycemic risk. The use of technologies applied to diabetes has been shown to improve glycemic control, however data in dialysis patients are limited. To describe the efficacy and safety of the minimed 780G AHCL system in a stable hemodialysis patient and during hospitalization in the Intensive Care Unit (ICU).
View Article and Find Full Text PDFJAMA Pediatr
September 2025
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Research Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada.
Importance: Youth living with type 1 diabetes (T1D) are increasingly choosing automated insulin delivery (AID) systems to manage their blood glucose. Few systematic reviews meta-analyzing results from randomized clinical trials (RCTs) are available to guide decision-making.
Objective: To study the association of prolonged AID system use in an outpatient setting with measures of glucose management and quality of life in youth with T1D.
Cureus
August 2025
Internal Medicine, Dr. Samir Abbas Hospital, Jeddah, SAU.
Type 2 diabetes (T2D) requires rigorous glycemic control to prevent complications, but traditional self-monitoring of blood glucose (SMBG) offers limited insights. Real-time continuous glucose monitoring (RT-CGM) provides dynamic data to optimize management, although its efficacy in T2D remains debated. This systematic review synthesizes evidence from randomized controlled trials (RCTs) to evaluate RT-CGM's impact on glycemic outcomes in adults with T2D.
View Article and Find Full Text PDFMetabol Open
September 2025
Department of Surgery, The Royal Hospital, Ghala St, Muscat, Oman.
Dumping syndrome (DS) is a known complication following bariatric surgery, caused by rapid gastric emptying into the small intestine. It presents in two forms: early dumping, with gastrointestinal and vasomotor symptoms occurring within 30-60 min after meals; and late dumping, which arises 1-3 h postprandially due to reactive hypoglycaemia. Standard management includes dietary changes and medications, but tolerability and long-term efficacy are variable.
View Article and Find Full Text PDF